Drug Profile
Research programme: antibacterials - ABAC Therapeutics
Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator ABAC Therapeutics
- Class Anti-infectives; Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acinetobacter infections; Staphylococcal infections; Streptococcal infections
- Discontinued Escherichia coli infections; Klebsiella infections; Pseudomonal infections
Most Recent Events
- 29 Aug 2023 Early research development is ongoing in Acinetobacter infections in Spain (unspecified route) (ABAC Therapeutics pipeline, August 2023)
- 29 Aug 2023 Discontinued for Escherichia coli infections in Spain (unspecified route) (ABAC Therapeutics pipeline, August 2023)
- 29 Aug 2023 Discontinued for Klebsiella infections in Spain (unspecified route) (ABAC Therapeutics pipeline, August 2023)